A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2017
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin; Pertuzumab; Trastuzumab
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms G7; GeparSepto
- 09 Dec 2017 Results assessing survival analysis presented at the 40th Annual San Antonio Breast Cancer Symposium.
- 07 Dec 2017 According to a Celgene Corporation media release, The German Breast Group and Celgene Corporation announced -term invasive disease-free survival results at the 2017 San Antonio Breast Cancer Symposium (SABCS).
- 07 Dec 2017 Results presented in a Celgene Corporation media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History